Elliot Silk

Three structural bets on where drug discovery infrastructure is heading.

A PhD synthetic organic chemist’s perspective on where untapped investment leverage sits in drug discovery.

Lab Automation
high conviction

Lab Automation & Closed-Loop Drug Discovery

Robotics, not AI, is the bottleneck. The build step has not kept pace with the design step.

7

Companies tracked

6

Challenges catalogued

5

Counterarguments addressed

Read thesis memo
Drug Discovery Biology
high conviction

Target identification, not the drug itself, is the key challenge in first-in-class therapeutics

The industry has a chemistry execution problem only because it first has a biology selection problem.

6

Companies tracked

6

Challenges catalogued

5

Counterarguments addressed

Read thesis memo
Consumer Health & Wellness Infrastructure
medium-high conviction

The wellness market will continue to expand, and the infrastructure layer, not the molecules, is where durable returns are generated

Wellness is undergoing a structural shift from discretionary lifestyle spending to science-backed preventive medicine.

6

Companies tracked

5

Challenges catalogued

5

Counterarguments addressed

Read thesis memo

Inter-thesis connections

Thesis 1 → Thesis 2:Better robotic synthesis generates richer biological datasets for target validation.
Thesis 2 → Thesis 3:Better target identification for peptide therapeutics accelerates the clinical credentialing of consumer wellness compounds.
Thesis 1 → Thesis 3:Automated synthesis infrastructure reduces the cost and time to manufacture novel peptide formulations for the wellness market.

Scope

Drug discovery infrastructure, lab automation, and enabling technologies for biotech

Edge

PhD research in transition metal catalysis and synthetic organic chemistry